A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management

Josep Castellvi, Assumpció Pérez-Benavente, Antonio Gil-Moreno, Melissa Bradbury, Eva Borràs, Marta Vilar, Jose Luis Sanchez Iglesias, Anna Fàbrega-Santamaria, Eduard Sabidó

Research output: Contribution to journalArticleResearchpeer-review

Abstract

High-grade serous carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer. Although most patients will initially respond to first-line treatment with a combination of surgery and platinum-based chemotherapy, up to a quarter will be resistant to treatment. We aimed to identify a new strategy to improve HGSC patient management at the time of cancer diagnosis (HGSC-1LTR). A total of 109 ready-available formalin-fixed paraffin-embedded HGSC tissues obtained at the time of HGSC diagnosis were selected for proteomic analysis. Clinical data, treatment approach and outcomes were collected for all patients. An initial discovery cohort (n = 21) were divided into chemoresistant and chemosensitive groups and evaluated using discovery mass-spectrometry (MS)-based proteomics. Proteins showing differential abundance between groups were verified in a verification cohort (n = 88) using targeted MS-based proteomics. A logistic regression model was used to select those proteins able to correctly classify patients into chemoresistant and chemosensitive. The classification performance of the protein and clinical data combinations were assessed through the generation of receiver operating characteristic (ROC) curves. Using the HGSC-1LTR strategy we have identified a molecular signature (TKT, LAMC1 and FUCO) that combined with ready available clinical data (patients' age, menopausal status, serum CA125 levels, and treatment approach) is able to predict patient response to first-line treatment with an AUC: 0.82 (95% CI 0.72-0.92). We have established a new strategy that combines molecular and clinical parameters to predict the response to first-line treatment in HGSC patients (HGSC-1LTR). This strategy can allow the identification of chemoresistance at the time of diagnosis providing the optimization of therapeutic decision making and the evaluation of alternative treatment strategies. Thus, advancing towards the improvement of patient outcome and the individualization of HGSC patients' care. The online version contains supplementary material available at 10.1186/s12967-022-03816-7.
Original languageEnglish
JournalJournal of Translational Medicine
Volume20
DOIs
Publication statusPublished - 2022

Keywords

  • Biomarker
  • High-grade serous ovarian cancer
  • Prediction
  • Proteomics
  • Treatment

Fingerprint

Dive into the research topics of 'A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management'. Together they form a unique fingerprint.

Cite this